

# STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

### **DEFEROXAMINE**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DEFEROXAMINE	DESFERAL,	01104		GPI-10	
MESYLATE	DEFEROXAMINE			(9300002010)	
	MESYLATE				

#### **GUIDELINES FOR USE**

## INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- 1. Does the patient have a diagnosis of chronic iron overload due to transfusion-dependent anemias and meet **ALL** of the following criteria?
  - The medication is prescribed by or given in consultation with a hematologist or hematologistoncologist
  - The patient is 3 years of age or older
  - The patient has a serum ferritin levels that are consistently greater than 1000mcg/L (at least 2 lab values in the previous 3 months)

If yes, approve for 6 months by HICL or GPI-10.

If no, do not approve.

INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **DEFEROXAMINE** (**Desferal**) requires the following rule(s) be met for approval:

- A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
- B. Therapy is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist-oncologist (tumor/cancer doctor)
- C. You are 3 years of age or older
- D. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 1000mcg/L (shown by at least 2 lab values in the previous 3 months)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

## **CONTINUED ON NEXT PAGE**

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 3/31/2023 Page 1 of 2



# STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

#### **DEFEROXAMINE**

### **GUIDELINES FOR USE (CONTINUED)**

#### **RENEWAL CRITERIA**

- 1. Does the patient have a diagnosis of chronic iron overload due to transfusion-dependent anemias and meet the following criterion?
  - The patient has a serum ferritin levels that are consistently greater than 500mcg/L (at least 2 lab values in the previous 3 months)

If yes, approve for 12 months by HICL or GPI-10. If no, do not approve.

RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **DEFEROXAMINE** (**Desferal**) requires the following rules be met for renewal:

- A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
- B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 500mcg/L (at least 2 lab values in the previous 3 months)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

#### **RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Desferal.

#### **REFERENCES**

Desferal [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;
September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 08/17

Commercial Effective: 04/17/23 Client Approval: 03/23 P&T Approval: 07/17

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 3/31/2023 Page 2 of 2